Posted: July 26th, 2016

elapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long­Acting Injectable vs Quetiapine: Results of a Long­Term

1. Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long­Acting Injectable vs Quetiapine: Results of a Long­Term, Open­Label, Randomized Clinical Trial 2.A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia 3. An Exploratory, Open­Label, Randomized Trial Comparing Risperidone Long­Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis 4.Depot and oral antipsychotics: patient preferences and attitudes are not the same thing 5.Descriptive analyses of the aripiprazole arm in the risperidone long­acting injectable versus quetiapine relapse prevention trial (ConstaTRE) 6.First­generation antipsychotic long­acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies 7.Long­acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebocontrolled relapse prevention studies 8.Long­Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta­Analysis of Randomized Trials 9.Long­Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia 10.Maintenance Treatment With Long­Acting Injectable Risperidone in First­Episode Schizophrenia: A Randomized Effectiveness Study 11.Olanzapine Long­Acting Injection: A 24­Week, Randomized, Double­Blind Trial of Maintenance Treatment in Patients With Schizophrenia 12.Oral versus depot antipsychotic drugs for schizophreniaA critical systematic review and meta­analysis of randomised long­term trials 13.Oral versus Long­Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review